Fulcrum Therapeutics (FULC) Cash from Investing Activities (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Cash from Investing Activities data on file, last reported at -$128.2 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 16400.64% year-over-year to -$128.2 million in Q1 2026; TTM through Mar 2026 was -$96.7 million, a 1348.9% decrease from a year earlier, with the FY2025 full-year figure at $30.7 million, down 4.69% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$128.2 million, down from -$1.0 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for FULC reached as high as $38.1 million in Q1 2024 and fell as low as -$128.2 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged -$5.3 million across 5 years, with a median of $4.4 million in 2024.
• Across the five-year window, Cash from Investing Activities soared 934.58% in 2023 and sank 16400.64% in 2026, its largest moves.
• Year by year, Cash from Investing Activities stood at -$36.4 million in 2022, then soared by 150.48% to $18.4 million in 2023, then slumped by 87.69% to $2.3 million in 2024, then plunged by 146.42% to -$1.0 million in 2025, then sank by 12122.12% to -$128.2 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$128.2 million in Q1 2026, -$1.0 million in Q4 2025, and $18.6 million in Q3 2025.